Princess Alexandra Hospital
Radiation Oncology
2019 Research Report
Message from Director of Research
Radiation Oncology
Princess Alexandra Hospital
Professor Sandro Porceddu
It has been an outstanding research year reflecting our ongoing commitment to delivering quality care through the integration of research into our clinical service. In 2019 the Princess Alexandra Hospital Radiation Oncology department received several prestigious awards in recognition of research excellence.
This included the Varian Prize at the Australian and New Zealand College of Radiologists and the best oral and poster prize at the Engineering & Physical Sciences in Medicine Conference.
In collaboration with Professor Ian Frazer, former Australian of the Year and developer of the Gardisil Vaccine we were awarded the Outstanding Collaboration in Research & Development prize by the Business and Higher Education Research and Technology (BHART) Awards Committee.
Through our many collaborations we were involved in receiving close to $7 million in grant funding. Our national and global reach remained relatively high with 100 national and international presentations and 33 peer-reviewed publications.
The department continues to foster and supervise higher degrees with students completing Honours, Masters & PhD’s.
We would like to take this opportunity to acknowledge the generous support received from PA Research Foundation, Metro South Health Study Education and Research Trust and donors.
We would like to thank all of our research partners including, TRI, QFAB, University of Queensland and QUT.
We would also like to thank our patients who kindly volunteer to participate in our clinical trials.
Sandro V Porceddu
Message from Manager of
Cancer Trials Unit (CTU)
Division of Cancer Services
Princess Alexandra Hospital
Adrienne See
Emerging technology trials have again dominated the Radiation Oncology Trials landscape in 2019, many combining with immunotherapy, thus offering patients access to otherwise unavailable treatments. Of the four new studies opened at CTU in 2019, 2 of these (NINJA, MASTERPLAN) are utilising Stereotactic (SBRT) technology, whilst 1 (OUTRUN) is combining SBRT and immunotherapy. Three studies closed to recruitment during the year, whilst one closed to follow up.
Over the course of the year, 174 potential patients were screened for trials, with 22 patients successfully recruited at the ROPART site and 31 at ROPAIR, yielding a recruitment rate of 31%. ROPART has again been hindered by trial selection due to the lack of required equipment for the emerging technology trials, but with the long overdue installation of new radiotherapy machines in the second half of 2020, we are looking forward to being able to offer these trials to all patients within the Metro South catchment area.
Towards the end of the year, it was with disappointment that ROPART’s long standing trials partnership with Mater Cancer Care Centre came to an end. However, this has led to an exciting opportunity to collaborate with our private sector colleagues, ICON Cancer Care. This new collaboration, whilst in its infancy, may see much-needed access to more industry trials.
One such trial is the C-POST study – the long-awaited follow-up trial to the POST Study which was conducted at both sites in years past. The C-POST study opened to recruitment in early 2020 at ROPAIR, and with the collaboration with ICON, it is hoped to open at ROPART in mid-2020. It is the first industry trial Radiation Oncology has conducted in many years.
The Cancer Trials Unit - Radiation Oncology Team has continued our proud record of the highest quality of trials conduct both on a national and international level – none of which would be possible without the contribution of staff from all disciplines and least of all from our patients. I am always humbled by the altruistic dedication of our patients who willingly and selflessly contribute to the evolution of cancer therapy.
Adrienne See
Manager, Clinical Trials Unit
Cancer Services
Princess Alexandra Hospital
Individual Achievements
Awards & Prizes
Matthew Foote
University of Toronto Department of Radiation Oncology Alumni of the Year 2019 - In recognition of Outstanding Contribution to Radiation Medicine and the University of Toronto’s Department of Radiation Oncology Community.
Sau Fan Liu, Venkatakrishnan Seshadri, Catherine Jones, Thanh Bui, Sandro V Porceddu
Winner “Best Oral Presentation, Imaging”.
Pilot study of 18F-FDG PET quantitative analysis in head and neck cancer patients.
Engineering & Physical Sciences in Medicine Conference (EPSM). Perth, Australia, October 2019.
Luke Webb, Emma Horgan, Christopher Noble
Winner “Best Poster Presentation, Radiation Oncology”.
Artefact correction with EPIgray: an EPID based in-vivo dosimetry solution.
Engineering & Physical Sciences in Medicine Conference (EPSM). Perth, Australia, October 2019.
Ian Frazer, Janin Chandra, Neil Finlayson, Yvonne Woo, Yan Xu, Sandro V Porceddu
Winner, “Outstanding Collaboration in Research & Development Category: New Enterprises”.
2019 Business and Higher Education Research and Technology Awards.
Polynucleotide-based immunotherapy to treat chronic viral infections and associated diseases.
Chris Williams, Howard Liu, Elizabeth Brown, Rob Milne, Margaret McGrath, Rahul Ladwa, Matthew Foote, Ben Panizza, Sandro V Porceddu
2019 The Royal Australian and New Zealand College of Radiologists Varian Prize Winner, Auckland, New Zealand.
The diminishing role of neck dissection in node positive HPV-associated oropharyngeal cancer following (chemo) radiotherapy.
Grants and Funding
Projects and Recipients
Enhancing speech pathology outpatient models of care in regional services for patients with head & neck cancer.
Allied Health Professions’ Office of Queensland Health Practitioner Research Scheme – Experienced Researcher Grant $95,808, 2019–2021.
Ward EC, Burns C, Graham N, Nund R, Wall L, Foley J, Comben W, Missenden E.Proof of concept: What are the tangible benefits of an allied health clinical- research service the Division of Cancer Services, Metro South Hospital and Health Services.
Metro South Hospital and Health Service, Study Education Research Trust Account $196,724, 2019–2021.
Brown B, Walpole E, Ward E, Grudzinskas K, Whitehead M, Chan R, Stone L.Radiotherapy and immunotherapy for breast cancer brain metastases and glioblastoma.
Brisbane Diamantina Health Partners Cancer Theme Grant 2019 $17,500.
Pinkham M, Mazzieri R (UQ), Fontaressi D (QUT).Head and neck lymphoedema treatment: An examination and development of current standards of care.
PA Research Foundation Grant 2019 $100,000.
Pigott A, Nixon J, Cartmill B, Porceddu S, McCann A, McPhail S, Jeans C, Trevethan M, Panizza B.Improving cardiovascular health outcomes in women undergoing irradiation for breast cancer; investigating new cardiac imaging modalities and reviewing cardiac structure injury from radiation therapy.
PA Research Foundation Grant 2019 $100,000.
Lehman M, Ng A, Dong X, Galloway G, Harvey J, Mai T, Browne P, Beaton N, Sharma H.A remote surveillance model of care to reduce cost and resource demand when monitoring for lymphoedema after breast cancer.
Health Practitioner Research Scheme 2019 $28,927. Hides J, Pinkham E, Pigott A.A Phase Ib, single centre, open label study of a therapeutic Human Papillomavirus (HPV) DNA vaccine co-administered with anti-PD-L1 immunotherapy, Durvalumab (MEDI4736), for recurrent and/or metastatic HPV-related oropharyngeal cancer.
TRI DRIVE Grant. DurVax Trial $250,000, 2019–2021.
Porceddu S, Frazer I, Ladwa R, Panizza B.Centre for Personalised Analysis of Cancers: Clinician Researcher Training at the Translational Interface.
Medical Research Future Fund Rapid Applied Research Translation Program $1,150,000, 2019–2021.
Principal Investigator: Thompson E. Chief Investigators: Walpole E, Williams E, Bray L, Brown M, Day B, Haass N, Hughes B, O’Byrne K, Simpson F, Vela I, Dolcetti R, Leo P, Richard D, Whitehall V, Winkler I, Atkinson V, Foote M, Kenny L, Khanna R, Marlton P, Mazzieri R, Pinkham M, Pollock P, Punyadeera C, Schaider H, Snell C, Theile D, Waugh D, Batra J, Bettington M, Burge M, Chua B, Cuff K, Doran M, Clarke P, Gabrielli B, Gunter J, Henriques S, Hudson J, Kenna T, Kijanka G, Kulasinghe A, Khosrotehrani K, Lakhani S, Leggett B, Lwin Z, Malycha P, Nelson C, Pearson J, Robinson J, Radford K, Rose S, Russell P, Smith A, Soyer P, Thomas P, Waddel N, Perrin L, Noske K.A novel Spherical Array Detector for Patient-Specific Quality Assurance of Stereotactic Radiotherapy/ Radiosurgery treatment plans.
Metro South Health Research Support Scheme Innovation (Seed) Grant 2019– $21,900.
Ramachandran P, Pinkham M.MAGMA: Multi-Arm GlioblastoMa Australasia Trial.
Medical Research Future Fund Research Grants - Brain Cancer $2,422,000, 2019–2024.
Principal Investigators: Gedye C, Nowak A, Hovey E, Eng-Siew K, Harrup R, Parkinson JF, Barnes E, Jeffree R, Associate Investigator: Pinkham M.s.PROMISE: Patient-Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience.
Cancer Council Queensland Accelerating Collaborative Cancer Research Grant $2,000,000 ($1.4mil
Cancer Council Queensland $600k contribution Queensland Institute of Medical Research), 2020–2023.
Webb P, Chan R, Brown B, Wyld D, Sabesan S, Gordon L, Hartel G, Girgis A, Eastgate M, Sanmugarajah J, Wishart L, Nund R, Doyle M, Miller E.Statewide implementation of electronic patient-reported outcome monitoring (ePROMs) to optimize allied health services for Queenslanders with head and neck cancer.
Allied Health Office of Queensland Implementation Grant 2019 $132,656.
Wishart L, Brown B.Magnetic resonance Imaging RAdiomics relationships with GEnomics and outcome of breast cancer in NeoAdjuvant Treatment setting (MIRAGE-NAT). Metro South Health Research Support Scheme Project Grant $62,400, 2020–2021.
Santamaria G, Lakhani S, Rahul L, Ramachandran P, Lloyd T, Bennett I.Genomic characterisation of sinonasal undifferentiated carcinomas.
Metro South Health Research Support Scheme Innovation (Seed) Grant $19,208, 2019.
Trinh H, Patch AM, Cooper C, Porceddu SV.Evaluating and enhancing the adoption of short-course prostate cancer radiotherapy in Australia.
Prostate Cancer Outcomes Registry Australia and New Zealand (PCOR-ANZ) Quality Improvement Research Fund $100, 000, 2019–2020.
Principal Investigators: Pryor D, Day H, Martin J, Turner S, Hayden A, Skala M, Fitzgerald L, Chan R, Ong W, Pase M, Miller J.Identifying barriers to active surveillance for low-risk prostate cancer in Australia and New Zealand.
Prostate Cancer Outcomes Registry Australia and New Zealand (PCOR-ANZ) Quality Improvement Research Fund $100, 000, 2019–2020.
Lawrentschuk N, Thangasamy I, Ong W, Evans S, Pritchard E, Murphy D, Mark S, Chalasani V, Rashid P, Wintr M, Vela I, Millar J. Associate Investigator: D Pryor.
Research in Focus
Radiotherapy technology in the treatment of movement disorders
Stereotactic Radiosurgery (SRS) thalamotomy for tremor has been provided at the Gamma Knife Centre of Queensland, Princess Alexandra Hospital, since January 2018. SRS presents as an option for patients suffering from disabling tremor who are unfit for deep brain stimulation and refractory to medical treatment.
SRS Thalamotomy has been performed on ten patients. All patients have received a single fraction dose of 120Gy to 130Gy to the lateral portion of the ventral intermediate (VIM) nucleus of the thalamus. Patients are in various stages of follow-up through the Metro South Movement Disorders Service, monitoring for continued symptom remission, maximal response and side effects.
To date, the technique of delivering this treatment and the supporting patient case studies have been the subject of multiple presentations and posters to different audiences. This is anticipated to increase in the forthcoming years as the patient numbers and follow up data grow.
DurVax Trial in Head and Neck Cancer
Human Papillomavirus (HPV) mediated throat cancer is now the most common head and neck cancer in Queensland. In collaboration with Professor Frazer from the University of Queensland, Jingang Medicine (Australia), Astra Zeneca, Metro South Health and the TRI a world-first trial exploring the role of a newly developed therapeutic HPV-vaccine in combination with an immune checkpoint inhibitor are being tested in head and neck cancer patients.
This trial has now commenced accrual. This trial follows on from a recently completed first-in-human trial of the vaccine completed at the Princess Alexandra Hospital and the Clinical Research Facility.
Investigating brain low dose wash in the treatment of SRT for singular brain metastases
The Radiation Oncology department is currently examining the role of a form of treatment known as Hypofractionated Stereotactic Radiotherapy (HF-SRT) for the treatment of brain metastases. Led by Erin Johns and the radiation therapy team, this treatment combines highly precise radiation therapy and fewer doses of treatment to tumours that have spread to the brain. This research utilises predictive radiation therapy planning models to deliver high quality cancer treatment by reducing the dose of radiation to the normal or unaffected brain. Early data is promising and further work in this area will be conducted in 2020.
Cancer Wellness initiative and research
Cancer survivors report emotional, psychological, physical and practical challenges in the years following treatment. The goal of this initiative is to promote a greater co-ordinated and person-centred care. With the support of The Queensland Collaborative for Cancer Survivorship, and a $200,000 Innovation grant from the PAH Research Foundation, the PAH is the first quaternary hospital in Queensland to bring together consumers, researchers, expert clinicians, health system executives, technology and telehealth experts, and community representatives to explore the pilot implementation of a Wellness Initiative. Several members from the Radiation Oncology Department form part of the key investigative team of this vital research.
Positron Emission Tomography (PET) in predicting treatment response following radiotherapy in Head and Neck Cancer patients
One of the holy grails of cancer treatment is being able to predict which patients are likely to respond to curative radiotherapy. The value of this is that it can guide the clinician to how intensive the treatment needs to be. In her award-winning project, Eva Liu from the Physics department has performed some predictive modelling utilising the imaging characteristics of the tumour on the pre-treatment PET scans to predict which patients are likely to respond to radiotherapy and subsequently do not require additional surgery after treatment. Her pilot study has shown promise and further research is being conducted to validate her findings in a larger cohort of patients.
Research in Higher Degrees
Masters Projects
Alisha Wintour
Development and Evaluation of an Information Pamphlet for HPV Positive Oropharyngeal Cancer patients.
Queensland University of Technology.
Supervisors - E Brown, SV Porceddu, P Yates, S Chambers.
Erin Johns
Investigating brain low dose wash in the treatment of stereotactic radiotherapy for singular brain metastases.
Queensland University of Technology.
Supervisors – T Barry, M Pinkham, C Hargrave, L Nissen.
Christopher Noble
EPR Dosimetry for Measuring Very Small Fields in Modern Radiotherapy.
Queensland University of Technology.
Supervisors - B Perrett, E Horgan.
Hashim Alghamdi
Assessment of CT Metal Artifact Reduction Algorithm (O-MAR).
Queensland University of Technology.
Supervisors – Ramachandran P, Perret B, Trapp J.
Shybi Thomas (QUT)
Evaluation of an in-house semi-automated contouring tool in delineating lung gross tumour volume.
Queensland University of Technology.
Supervisors – Ramachandran P, Jones C, Trapp J.
Abdullah Al-Kabkabi (QUT)
Assessment of CBCT image quality and dose for commonly used pre-sets in external beam radiotherapy.
Queensland University of Technology.
Supervisors – Ramachandran P, Trapp J.
Honours Projects
Emily Nancy Yu
Stereotactic Radiation Therapy for Multiple Metastasis – A Treatment Planning Study.
RMIT University.
Supervisors – Deb P, Ramachandran P, Ryan J.
Yan Ru Chia
On the use of electronic compensators in external beam radiotherapy.
RMIT University.
Supervisors – Deb P, Ramachandran P, Ryan J.
PHD Projects
Alana Hutchison
Utilising dosimetric information to enhance the clinical management of dysphagia in patients undergoing (chemo)radiotherapy for head and neck cancer (HNC).
University of Queensland School of Health and Rehabilitation Services.
Supervisors - B Brown, L Wishart, E Ward.
Jodie Nixon
Distress in Head and Neck Cancer: Addressing the problem, supporting the patient, enhancing health professional engagement.
University of Queensland School of Health and Rehabilitation Services.
Supervisors - B Brown, J Turner, A Pigott.
Hassan Albarakati
Modelling of adaptive radiotherapy in lung cancer.
RMIT University.
Supervisors – P Ramachandran P, Jackson P, Geso M.
Ajeet Mishra
On Minimizing Influence of Interplay effect for the Stereotactic Body Radiotherapy (SBRT) of Lung tumour.
Queensland University of Technology.
Supervisors – P Ramachandran P, Fontanarosa D, Fielding A.
Presentations
Dulfikar A, Eng-Siew K, Lwin Z, Hovey E, Dhilon H, Pinkham M, Arundell J, Pinkham E, Foo J, Hides J, Naumann F. Can an individualised exercise program assist in maintenance of HRQOL in low and high-grade glioma patients undergoing post-operative chemoradiotherapy? Cancer Survivorship National Conference, Sydney, Australia, March 2019. Oral and Poster presentation.
Hutchison A, Cartmill B, Wall L, Ward E, Hargrave C, Brown E. Knowledge and practices of speech pathologists and radiation therapists regarding radiation dose and implications for dysphagia management. Dysphagia Research Society 27th Annual Scientific Meeting, San Diego, USA, March 2019. Oral presentation.
Brown B, Wishart L, Ward EC, Coleman A, Packer E, Sutherland K. Do cancer clinicians identify the health service needs of patients and their families? Cancer Survivorship, Sydney, Australia, March 2019. Oral and Poster presentation.
Brown B, Wishart L, Ward E, Chan R, Packer E, Coleman A. ScreenIT; Development, validation, implementation, and expansion of a web-based patient-reported outcome screening tool. Cancer Survivorship National Conference, Sydney, Australia, March 2019. Poster presentation.
Puffett A. Digital Publishing in Health Care - Ebook Design and Distribution for Patients Attending the Princess Alexandra Hospital Radiation Oncology Department. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral presentation.
Crowley S. Gamma Knife® Icon™ and the Development of an Adaptive Planning Workflow. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral presentation.
Johns E, Barry T, Bernard A, Brown E, Pinkham M. Investigating brain low dose wash in the treatment of stereotactic radiotherapy for singular brain metastases. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral and Poster presentation.
Porceddu S. Evolution of management of the neck through interdisciplinary collaboration. Australian Society of Otolaryngology and Head and Neck 69th Annual Scientific Meeting, Brisbane, Australia, March 2019. Invited speaker.
Porceddu S. Identifying the Supra High-risk Group within the POST (TROG 05.01) Study. American Head and Neck Society Annual Meeting, Austin, Texas, USA, May 2019. Invited speaker.
Porceddu S. Complexities in the Care of Non-Melanoma Skin Cancer. American Head and Neck Society Annual Meeting, Austin, Texas, USA, May 2019. Invited Panelist.
Porceddu S. The evolution and role of immunotherapy in head and neck cancer. Brisbane Immunotherapy, Brisbane, Australia, May 2019. Invited speaker.
Pinkham M. Role of adjuvant radiotherapy for stage 3 melanoma in era of immunotherapy. Brisbane Melanoma Interest Group, Brisbane, Australia, March 2019. Invited speaker.
Cubis L, Ownsworth T, Pinkham M, Foote M, Chambers S. Use of social identity mapping to understand the impact of brain tumour on social groups and identity: A qualitative study. ASSBI-NZRA, Wellington, New Zealand, May 2019. Oral Presentation.
Lusk R. Stereotactic radiosurgery for tremor: A case study. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral Presentation.
Jenkins M. The implementation of Icon™ to an existing Gamma Knife®: successes and challenges. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral Presentation.
Mclean M, Fogarty G. Radiomics: The Future of Personalised Radiation Therapy. ASMIRT/AACRT Student Conference, Adelaide, Australia, March 2019. Oral Presentation.
Hargrave C, Hickey B, Rose P, Zawlodzka-Bednarz S, Wallace N, Lehman M, Pallesen R, Edeling D, Robbie K, Scull A, Hewitt S, Bernard A. Coordination and resource considerations for a multi-centre trial comparing a silicon-based gel with standard care for radiation dermatitis. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral presentation.
Jones S (ROPART), Holt T, Deegan T, Wright K, Lehman M, Pryor D, Hargrave C, Mengersen K. Developing a Predicting Selection Framework for Hydrogel Implantation in Prostate Cancer Radiation Therapy. ASMIRT/AACRT, Adelaide, Australia, March 2019. Oral presentation.
Brown B, Wishart L, Ward EC, Coleman A, Packer E, Hutchison A. What factors contribute to distress in carers of patients undergoing radiotherapy for head and neck cancer? Cancer Survivorship, Sydney, Australia, March 2019. Poster presentation.
Brown B, Nixon J, McKinnell E, Wishart L, Walpole E, Stone L, Chan R, Whitehead M, Ward E, Puffett A, Gardner T, Hanley B, Miller E. Using an experience-based co-design process to co-create cancer wellness services for patients and their families. Cancer Survivorship, Sydney, Australia, March 2019. Poster presentation.
Brown B, Wishart L, Ward EC, Coleman A, Packer E. Do cancer clinicians identify the health service needs of patients and their families? Speech Pathology Australia and New Zealand Speech Therapy Association National Conference, Brisbane, Australia, June 2019. Oral presentation.
Hutchison A, Brown B, Wishart L, Ward E, Hargrave C, Brown E. Exploring clinical practices and inter-professional relationships of speech pathologists and radiation therapists working in head and neck cancer care. Speech Pathology Australia and New Zealand Speech Therapy Association National Conference, Brisbane, Australia, June 2019. Oral presentation.
Hutchison A, Brown B, Wishart L, Ward E. Can active sparing of the swallowing structures during radiotherapy for head and neck cancer reduce dysphagia severity? A scoping review. Speech Pathology Australia and New Zealand Speech Therapy Association National Conference, Brisbane, Australia, June 2019. Poster presentation.
Nund R, Brown B, Patterson J, Scarinci N, Ward E, Porceddu SV. Measuring the impact of dysphagia on family members. Speech Pathology Australia and New Zealand Speech Therapy Association National Conference, Brisbane, Australia, June 2019. Oral presentation.
Garimall S, Shanker M, Johns E, Watkins T, Olson S, Huo M, Foote M, Pinkham M. Evidence of dose-response following hypofractionated stereotactic radiotherapy to the cavity after surgery for brain metastases. Cooperative Trials Group for Neuro-Oncology (COGNO) Annual Scientific Meeting, Sydney, Australia, October 2019. Poster presentation.
Huo M, Shultz D, Laperriere N, Hodaie M, Cusimano M, Gentili F, Payne D, Berlin A, Schwartz M, Millar BA, Nassiri F, Zadeh G, Tsang D. Stereotactic radiosurgery for meningiomas: effect of dose on local control. ASTRO Poster Q&A Session, Chicago, USA, September 2019. Poster presentation.
Jenkins KS, Hall B, Pinkham M, Olson S, Foley H, Jenkins M, Huo M, Foote M. Gamma Knife Radiosurgery for large AVMs: The volume-staged approach. Neurosurgical society of Australia Annual Scientific Meeting, Melbourne, Australia, August 2019. Poster presentation.
Huo M, Foley H, Pinkham M, Jones C, Jenkins M, Thompson E, Olson S, Hall B, Watkins T, Foote M. Stereotactic radiotherapy for large vestibular schwannomas: volume change following radiosurgery versus hypofractionated stereotactic radiotherapy. International Stereotactic Radiosurgery Society Congress, Rio de Janeiro, Brazil, June 2019. Poster presentation.
Shankar M. Postoperative hypofractionated stereotactic radiotherapy (HSRT) for intracranial metastases: Relationship between dose and local control. RANZCR ASM, Auckland, October 2019. Oral presentation.
Shankar M. Postoperative hypofractionated stereotactic radiotherapy (HSRT) for intracranial metastases: Relationship between dose and local control. COGNO Scientific Meeting, Sydney, Australia, November 2019. Poster presentation.
Pinkham M. Centre for Personalised Analysis of Cancers (CPAC): Brain Tumour Stream collaborative workshop. Brisbane Cancer Conference, Brisbane, Australia, November 2019. Session chair.
Pinkham M. Modern management of brain metastases. Plenary session, Brisbane Cancer Conference, Brisbane, Australia, November 2019. Oral presentation.
Pinkham M. Role of adjuvant radiotherapy in stage 3 melanoma. Sunshine Coast melanoma interest group, Mooloolaba, Australia, November 2019. Invited Speaker.
Pinkham M. Radiation Therapy for Lung Cancer Brain Metastases. Lung Day 2019: The Future of Patient Care, Sydney, Australia, October 2019. Invited speaker.
Pinkham M. Connecting communities to advance cancer care. PAH Health Symposium, Brisbane, July 2019. Session Chair.
Lehman M, Michael M. Results of the Palliative Lung Cancer Trial (P-LUNG). Australian Lung Cancer Trials Group Meeting, Sydney, Australia, July 2019. Oral presentation.
Porceddu S. Looking closer at the Locally Advanced Squamous Cell Carcinoma Head and Neck treatment landscape. European Society of Medical Oncology Annual Scientific Meeting, Barcelona, Spain, September 2019. Invited Speaker.
Porceddu S. Practice defining research through inter-collaboration: an Australian contribution. Chris O’Brien Lifehouse Symposium 2019, Sydney, Australia, June 2019. Invited Speaker.
Porceddu S. Radiotherapy for cutaneous perineural invasion. Australian Skin Cancer Academy, Brisbane, Australia, September 2019. Invited Speaker.
Foote M. Stereotactic Spine Radiotherapy - Patient Selection. 14th ISRS (International Stereotactic Radiosurgery Society) Congress, Rio De Janeiro, Brazil, June 2019. Oral Presentation.
Foote M. Managing the Increasing Demands for Intracranial Radiosurgery Treatments in an integrated Oncology and Neurosurgical Setting. 14th ISRS Congress, Rio de Janeiro, Brazil, June 2019. Oral Presentation.
Foote M. Recent and Emerging Trends in Spinal Oncology. NSA (Neurosurgery Society of Australasia) ASM (Annual Scientific Meeting), Melbourne, Australia, August 2019. Oral presentation.
Foote M. Radiation Oncology: Materials and their effect on Radiation planning, dosing and patient outcome. NSA ASM, Melbourne, Australia, August 2019. Oral presentation.
Foote M. Stereotactic Radiosurgery in Brain Metastases - the changing landscape. NSA ASM, Melbourne, Australia, August 2019. Oral presentation.
Crowley S, Lusk R, Jenkins M, Foley H, Jones C, Pinkham M, Foote M. Gamma Knife Icon™ and the Development of an Adaptive Planning Workflow. PAH Research Excellence Symposium, Brisbane, Australia, July 2019. Poster presentation.
Foley H, Hall B, Foote M, Thompson E, Jenkins M. Multi-stage Gamma Knife Radiosurgery for large intracranial arterio-venous malformations. PAH Research Excellence Symposium, Brisbane, Australia, July 2019. Poster presentation.
Brandis P, Lusk R, Lehn A, Foote M, Nolan A, Charmley A, Pinkham M, Hall B, Olson S. Treatment of tremor at the Princess Alexandra Hospital with Gamma Knife Radiosurgery. PAH Research Excellence Symposium, Brisbane, Australia, July 2019. Poster presentation.
Brown E, O’Connor P, Eaves E, Pryor D. Motion pictures Assessing breath hold reproducibility in abdominal SBRT using Intrafraction Imaging. PAH Research Excellence Symposium, Brisbane, Australia, July 2019. Poster presentation.
Brown E. Motion pictures: Assessing breath-hold reproducibility in abdominal SBRT using Intrafraction Imaging. ASMIRT, Adelaide, Australia, March 2019. Oral Presentation.
Foyle M. MRI Simulator literature review. QLD ASMIRT weekend conference, Gold Coast, Australia, November 2019. Oral presentation.
McLean M. Knowledge based planning literature review. QLD ASMIRT weekend conference, Gold Coast, Australia, November 2019. Oral presentation.
Jacobson S, Chamunyonga C, Jenkins M, Lusk R, Jones C, Brown E. The Effect of MRI Distortion on Gamma Knife Radiosurgery Treatment Planning. QLD ASMIRT weekend conference, Gold Coast, Australia, November 2019. Oral presentation.
Nicol C, Cubis L, Ownsworth T, Pinkham M, Foote M. The impact of primary brain tumour on subjective cognitive functioning and associations with psychological distress. ASSBI-NZRA, Wellington, New Zealand, May 2019. Oral presentation.
Gonzalez M, Hong AM, Carlino MS, Atkinson V, Wang W, Lo S, Brown MP, Foote M, Pinkham M, Le H, Roos DE, Osorio M, Haghighi N, Kok D, Postow MA, McArthur GA, Menzies AM, Long GV. A Phase II, Open Label, Randomized Controlled Trial of Nivolumab Plus Ipilimumab with Stereotactic Radiotherapy versus Ipilimumab Plus Nivolumab Alone in Patients with Melanoma Brain Metastases (ABC – X Trial). ASCO Annual Meeting, Chicago, USA, May/June 2019, Oral presentation.
Brown B, Wishart L. ScreenIT: Innovative Technology for Patient Monitoring and Reporting. PA Health Symposium, Brisbane, Australia, July 2019. Oral presentation.
Cooney L Brown B. Good nutrition, eating and drinking. World Head and Neck Cancer Day Forum, Cancer Council Queensland, Brisbane, Australia, July 2019. Oral presentation.
Wishart L. Using technology to assist screening for supportive care needs in people with head/neck cancer and their families. World Head and Neck Cancer Day Forum, Princess Alexandra Hospital, Brisbane, Australia, July 2019. Oral presentation.
Brown B, Wishart L. ScreenIT: Innovative technology delivering patient-centred care for Queenslanders with cancer. Queensland Health Speech Pathology Advisory Committee Forum, Brisbane, Australia, September 2019. Oral presentation.
Brown B, Wishart L, Ward EC, Porceddu S, Courage M-J, Harrington J. The patterns of patient reported outcomes collected via a web-app during radiotherapy for head and neck cancer. Australia and New Zealand Head and Neck Cancer Society Annual Scientific Meeting, Adelaide, Australia, September 2019. Oral presentation.
Ramachandran P. (Biological Optimization & Radiomics), Fostering Medical Physics Research and clinical practice for better health care. CME on Advanced Radiotherapy Concepts, Chennai, India, August 2019. Invited Speaker.
Ramachandran P. Faculty - One day workshop: Python in Medical Physics - A technology of the era, Chennai, India, August 2019. Oral Presentation.
Leat C, Ramachandran P, Boyd J, Langton C, Chapman M. Monte Carlo modelling and verification of Tungsten Carbide electron applicator cut-outs. EPSM, Perth, Australia, October 2019. Poster presentation.
Abdullah A, Ramachandran P, Seshadri V. Assessment of cone beam CT Image Quality and Dose for varied projection images. EPSM, Perth, Australia, October 2019. Oral Presentation.
Esen N, Ramachandran P, Geso M. SABR pre-treatment verification using alanine and nanodot detectors. EPSM, Perth, Australia, October 2019. Poster presentation.
Ramachandran P, Perrett B, Seshadri V. A study on the use of GammaPlan convolution algorithm for dose calculation on CBCT images. EPSM, Perth, Australia, October 2019. Oral presentation.
Perrett B, Brown G, Lui SF. Commissioning ExaFlex™ superflab bolus for enhancement of surface dose to the chest wall/breast. EPSM, Perth, Australia, October 2019. Oral presentation.
Noble C, Liu SF, Hanlon P. The Effect of Gantry Sag on Patient Specific QA of Stereotactic Radiotherapy Plans. EPSM, Perth, Australia, October 2019. Oral presentation.
Noble C, Liu SF. Time Resolved Gamma Analysis in Patient Specific QA of VMAT Treatment Plans. EPSM, Perth, Australia, October 2019. Poster presentation.
Noble C, Liu SF, Ramachandran P. Automated plan checking of the Pinnacle TPS using Python. EPSM, Perth, Australia, October 2019. Oral presentation.
Liu SF, Liu H, Seshadri V, Jones CE, Bui T, Porceddu S. Pilot study of 18F-FDG PET quantitative analysis in head and neck cancer patients. EPSM, Perth, Australia, October 2019. Oral presentation.
Thomas S, Ramachandran P, Jones C. Evaluation of an in-house semi-automated contouring tool in delineating lung gross tumour volume. EPSM, Perth, Australia, October 2019. Oral presentation.
Brown G, Liu SF, Boyd J, Seshadri V, Wawrzak M. Validating a Clinical Electron Monte Carlo Model using both Low Melting Point Alloy and 3D-Printed Electron Inserts. EPSM, Perth, Australia, October 2019. Oral presentation.
Brown G, Jones C, Zawlodska S. Pacemaker Dose Estimates for Leksell Gamma Knife Patients. EPSM, Perth, Australia, October 2019. Oral presentation.
Jones CE, Perrett B, Webb L, Brown GPG. Independent dose verification of Leksell Gamma Knife treatment plans. EPSM, Perth, Australia, October 2019. Oral presentation.
Jones CE, Ramachandran P, Lehman M. Semi-automated segmentation of non-small-cell lung carcinoma (NSCLC) GTVs in cone beam computed tomography (CBCT) scans. EPSM, Perth, Australia, October 2019. Oral presentation.
Crowe SB, Whittle E, Jones C, Kairn T. “Dosimeter selection for small field percentage depth dose and tissue-maximum-ratio measurements”. ESTRO 38, Milan, Italy, April 2019. Poster presentation.
Hashim A, Perrett B, Ramachandran P. Assessment of Philips metal artefact reduction of orthopaedic implants (O-MAR) algorithm for radiotherapy planning datasets, EPSM 2019, Australia, October 2019. Poster presentation.
Ibrahim S, Liu SF, Perrett B, Hanlon P, Ramachandran P. Control Point Spacing Comparison for VMAT Optimisation. EPSM, Perth, Australia, October 2019. Poster presentation.
Perrett B, Lui SF. The importance of commissioning and on-going quality assurance of headrests for patient immobilisation. EPSM, Perth, Australia, October 2019. Poster presentation.
Seshadri V, Ibrahim S, Ramachandran P. Performance Comparison of 2D Arrays for Routine Profile Measurements and Analysis. EPSM, Perth, Australia, October 2019. Poster presentation.
Webb L, Horgan E, Noble C. Artefact correction with EPIgray: an EPID based in-vivo dosimetry solution. EPSM, Perth, Australia, October 2019. Poster presentation.
Daniels C. Patterns of care and changing demographics in head and neck cancer: A statewide population-based analysis. ANZHNCS ASM, Adelaide, Australia, September 2019. Oral presentation.
Daniels C. Patterns of care and changing demographics in head and neck cancer: A statewide population-based analysis. Plenary session, Brisbane Cancer Conference, Brisbane, Australia, November 2019. Oral presentation.
Porceddu SV. Evolving landscape of squamous cell carcinoma head and neck globally. Head and Neck Summit, Shanghai, China, November 2019. International Keynote Speaker.
Pryor D, Lee K, McLean K, Leggett D, Hodgkinson D, Fawcett J, Mott R, Stuart K, Pryor D. Australian experience of SBRT in early and advanced stage hepatocellular carcinoma. ESTRO meets Asia, Singapore, December 2019. Oral presentation.
Pryor D. Advancements in Radiation Oncology. World Head and Neck Cancer Day, Brisbane, Australia, July 2019. Invited Speaker.
Pryor D. Hypofractionated radiation therapy for prostate cancer. ASTRO Annual Meeting, Chicago, USA, September 2019. Invited Speaker.
Pryor D. Emerging indications for stereotactic radiation therapy – kidney cancer. 14th ISRS Congress, Rio de Janeiro, Brazil, June 2019. Invited Speaker.
Pryor D. Stereotactic radiation therapy for prostate cancer. 14th ISRS Congress, Rio de Janeiro, Brazil, June 2019. Invited Speaker.
Pryor D. Stereotactic radiation therapy for oligometastases. Australasian Society for Breast Disease Annual General Meeting, Gold Coast, Australia, October 2019. Invited Speaker.
Pryor D. Stereotactic radiation therapy for hepatocellular carcinoma. Hunter Cancer Research Alliance Symposium, Newcastle, Australia, November 2019. Invited Speaker.
Pryor D. Radiation therapy for retroperitoneal sarcoma. Australia and New Zealand Sarcoma Association Annual Scientific Meeting, Canberra, Australia, October 2019. Invited Speaker.
Pryor D. Interventional Onocology - Stereotactic radiation therapy for liver cancer. TROG 2019, Melbourne, Australia, 2019. Invited Speaker.
Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Martin J. Phase 2 multicentre study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS). 14th ISRS Congress, Rio de Janeiro, Brazil, June 2019. Oral presentation.
Siva S, Bressel M, Loi S, Sandhu S, Tran B, Mooi J, Lewin J, Azad A, Colyer D, Shaw M, Chander S, Cuff K, Wood S, Lawrentschuk N, Murphy, Pryor D. Safety of Pembrolizumab combined with stereotactive ablative body radiotherapy (SABR) for pulmonary oligometastases. Journal Thoracic Oncology. 2019;14(10):s248. IALSC World Conference on Lung Cancer, Barcelona, Spain, September 2019. Oral Abstract.
Siva S, Bressel M, Sandhau S, Tran B, Mooi J, Loi S, Lewin J, Toner G, Moon D, Goad J, Shaw M, Chander S, Eade T, Guminski A, Jayamanne D, Pryor D, Cuff K, Wood S, Lawrentschuk N, Murphy D. Interim safety analysis of RAPPORT trial – SABR with Pembrolizumab in oligometastatic RCC. Radiother Oncol. 2019;133:s137-s139. ESTRO 38, Milan, Italy, April 2019. Oral Abstract.
Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Martin J. Early results of a phase 2 multicentre study of linac-based stereotactic boost for prostate cancer. Radiother Oncol. 2019;133:s832-s833. ESTRO 38, Milan, Italy, April 2019. Oral Abstract.
Martin J, Blanchard P, Gree P, Keall P, Pryor D, Sidhom M, Siva S, Supiot S, Turner S. Oligometastatic prostate SBRT. Radiother Oncol. 2019;133:s355-s356. ESTRO 38, Milan, Italy, April 2019. Oral Abstract.
Pryor D, Liu H, Hodgkinson P, Leggett D, McLean K, Lee D, Mott R, Stuart K. Efficacy and toxicity of stereotactic radiation therapy for hepatocellular carcinoma. 14th ISRS Congress, Rio de Janeiro, Brazil, June 2019. Poster presentation.
Pryor D, Liu H, Hodgkinson P, Leggett D, McLean K, Lee D, Mott R, Stuart K. Efficacy and toxicity of stereotactic radiation therapy in early and advanced stage hepatocellular carcinoma. Gastroenterological Society of Australia Annual Scientific Meeting, Adelaide, Australia, September 2019. Poster presentation.
Publications
Indications for whole brain radiotherapy. Huo M, Moraes F, Foote M, Pinkham MB, Marta G, Suh J. In: E Chang editor. Radiotherapy and the Modern Management of Brain Metastases – A Case Based Approach. Springer. 2019.
Radiological Kinetics of Brain Metastases and Clinical Implications for Patients Treated With Stereotactic Radiosurgery. Nicholls LW, Pinkham MB, Bernard A, Lusk R, Watkins T, Hall B, Olson S, Foote MC. Clin Oncol. 2019;31(1):34-40.
Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy. Liu HY, Milne R, Lock G, Panizza BJ, Bernard A, Foote M, McGrath M, Brown E, Gandhi M, Porceddu SV. Oral Oncol. 2019;88:153-159.
Practices, knowledge and inter-professional relationships between speech pathologists and radiation therapists managing patients with head and neck cancer. Hutchison AR, Cartmill B, Wall LR, Ward EC, Hargrave C, Brown E. J Med Radiat Sc. 2019;66(2):103-111.
Dysphagia optimized radiotherapy to reduce swallowing dysfunction severity in patients undergoing treatment for head and neck cancer (HNC): a systematized scoping review. Hutchison A, Cartmill B, Wall LR, Ward EC. Head Neck. 2019;41(6):2024-2033.
Integral small field output factor measurements using a transmission ionisation chamber. De Chavez R, Jones CJ, Charles PH. Australas Phys Eng Sci Med. 2019;42(1):235-244.
Chapter 17: Central nervous system tumours. Burnet N, Harris F, Pinkham MB, Burton K, Whitfield GA. External Beam Therapy (Radiotherapy in Practice) 3rd Edition edited by P Hoskins. Oxford University Press. 2019.
The importance of staying connected: mediating and moderating effects of social group memberships on psychological wellbeing after brain tumor. Cubis L, Ownsworth T, Pinkham MB, Foote M, Legg M, Chambers S. Psycho-oncol. 2019;doi:10.1002/pon.5125 (Epub ahead of print).
What are we really measuring? A content comparison of swallowing outcome measures for head and neck cancer based on the International Classification of Functioning, Disability and Health (ICF). Nund RL, Brown B, Ward EC, Maclean J, Roe J, Patterson JM, Martino R. Dysphagia. 2019;34(4):575-591.
FDG-PET Response Assessment in Patients with Locally Advanced Nodal Melanoma Undergoing High-Dose Neo-Adjuvant or Definitive Radiotherapy. Trada Y, Law PW, Bernard A, Foote M, Barbour A, Lambie D, Smithers M, Burmeister B, Pinkham M. Int J Radiat Oncol - Official Journal of the ASTRO (American Society for Radiation Oncology). 2019;105(1):e799-e800.
A prospective examination of mask anxiety during radiotherapy for head and neck cancer and patient perceptions of management strategies.Nixon JL, Brown B, Pigott A, Turner J, Brown E, Bernard A, Wall L, Ward EC, Porceddu S. J Med Radiat Sc. 2019;66(3):184-190.
Content comparisons of tools used to assess swallowing in head and neck cancer based on the International Classification of Functioning, Disability and Health (ICF). Nund RL, Brown B, Ward EC, Maclean J, Patterson J, Roe J, Martino RM. Dysphagia. 2019;34(4):575-591.
Swallowing function and implications in head and neck cancer. Messing BP, Burns C, Wall LR, Brown B. In P. W. Flint et al. (Eds.), Cummings Otolaryngology (7th Edition). Elsevier. 2019.
Nutrition and swallowing therapy strategies for head and neck cancer patients. Boll Kristensen M, Isenring B, Brown B. Nutrition. 2019;69:110548 (Epub ahead of print).
Subjective cognitive functioning and associations with psychological distress in adult brain tumour survivors. Nicol C, Ownsworth T, Cubis L, Nguyen W, Foote M, Pinkham MB. J Cancer Survivorship. 2019;13(5):653-662.
Evaluation of a telehealth psychological support intervention for people with primary brain tumour and their family members: Study protocol for a randomised controlled trial. Ownsworth T, Chambers S, Aitken JF, Foote M, Pinkham MB, Gordon LG, Lock G, Hanley B, Gardner T, Jones S, Robertson J, Shum D, Conlon E. Eur J Cancer Care. 2019;28(2):e13132.
The importance of staying connected: Mediating and moderating effects of social group memberships on psychological well-being after brain tumor. Cubis L, Ownsworth T, Pinkham MB, Foote M, Legg M, Chambers S. Psycho Oncology. 2019;28(7):1537-1543.
Commentary: Postoperative Stereotactic Body Radiotherapy for Spinal Metastases and the Impact of Epidural Disease Grade. Vellayappan B, Kumar N, Foote M, Hofstetter CP, Saigal R, Chao ST, Lo SS. Neurosurgery. 2019;PII:nyz433.doi:10.1093/neuros/nyz433 (Epub ahead of print).
Commentary: Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases. Vellayappan B, Foote M, Redmond KJ, Chao ST, Lo SS. Neurosurgery.
2019 Nov;1;85(5):e870-e871.
Extent of surrounding edema does not correlate with acute complications after radiosurgery for melanoma brain metastases. Jardim A, Scott J, Drew Z, Foote MC, Sadasivan AP, Hall B, Olson SL, Shanker M, Pinkham MB. J Neurooncol. 2019;145(3):581-585.
Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Ratnayake G, Shanker M, Roberts K, Mason R, Hughes BGM, Lwin Z, Jain V, O’Byrne K, Lehman M, Chua B. Asia Pac J Clin Oncol. 2019;doi:10.1111/ajco.13242. (Epub ahead of print).
Identification of an excellent prognosis subset of human papillomavirus- associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. Solomon B, Young RJ, Bressel M, Cernelc J, Savas P, Liu H, Urban D, Thai A, Cooper C, Fua T, Neeson P, Loi S, Porceddu SV, Rischin D. Ann Oncol. 2019;30(10):1638-1646.
Development of a multicentre automated model to reduce planning variability in radiotherapy of prostate cancer. Panettieri V, Ball D, Chapman A, Cristofaro N, Gawthrop J, Griffin P, Herath S, Hoyle S, Jukes L, Kron T, Markham C, Marr L, Moloney P, Nelli F, Ramachandran P, Smith A, Hornby CJ. Phys Imag Radiat Oncol. 2019;11:34-40.
On the use of AAA and AcurosXB algorithms for three different stereotactic ablative body radiotherapy (SABR) techniques: Volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT) and 3D conformal radiotherapy (3D-CRT). Tajaldeen A, Ramachandran P, Alghamdi S, Geso M. Rep Pract Oncol Radiother. 2019;24(4):399-408.
A comprehensive phantom with multi-detector inserts for pre-treatment quality assurance in stereotactic ablative radiotherapy. Ramachandran P, Esen N, Tajaldeen A, Geso M, Taylor D, Archer P, Kron T. Journal of Physics: Conference Series. 2019;1154(1), 012022:2-5.
Brachytherapy utilising miniaturised X-ray tubes–clinical implementation and future applications. Ramachandran P, Wanigaratne D, Hagekrykou J, Roozen K, Geso M, Kron T, David S. Journal of Physics: Conference Series. 2019;1154(1), 012023:1–5.
Advanced adenoid cystic carcinoma of the skull base – The role of surgery. Guazzo E, Bowman J, Porceddu S, Webb L, Panizza B. Oral Oncol. 2019;99:104466.
Clinical practice guidelines for keratinocyte cancer – Radiotherapy. Fogarty G, Liu H. Cancer Council Australia. 2019.
Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng SP, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman KA, Chang DT, Kneebone A. Pract Radiat Oncol. 2019;pii: S1879-8500(19)30233-4. doi:10.1016/j.prro.2019.07.018.
Roberts M, Papa N, Perera M, Scott S, Teloken P, Joshi A, Vela I, Pryor D, Martin J, Woo H. Contemporary Nationwide Analysis of Surgery and Radiotherapy Treatment for Prostate Cancer. BIJU. 2019; https://doi. org/10.1111/bju.14773 (Epub ahead of print).
Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Sidhom M, Skala M, Yaxley J, Shakespeare TP. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2019;140:68-75.
Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Martin J. Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). Front in Oncol. 2019;doi.org/10.3389/fonc.2019.00217 (Epub ahead of print).
Martin J, Keall P, Siva S, Greer P, Christie D, Moore K, Dowling J, Pryor D, Chong P, McLeod N, Raman A, Lynam J, Smart J, Oldmeadow C, Tang CI, Murphy DG, Millar J, Tai KH, Holloway L, Reeves P, Hayden A, Lim T, Holt T, Sidhom M. TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol. BMJ Open. 2019;9(8):e030731.
Collaborative Trials Portfolio
-
^ Opened to recruitment in 2019
* Closed to recruitment in 2019
~ Closed to follow-up in 2019
Acknowledgements in preparing this report
Adrienne See, Melissa Scott, Harish Sharma, Andrew Puffett and the entire PAH Radiation Therapy Research Team.